Last reviewed · How we verify

SII Yellow Fever Vaccine

Serum Institute of India Pvt. Ltd. · Phase 3 active Biologic

This live attenuated yellow fever vaccine stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus.

This live attenuated yellow fever vaccine stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus. Used for Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas.

At a glance

Generic nameSII Yellow Fever Vaccine
SponsorSerum Institute of India Pvt. Ltd.
Drug classLive attenuated vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The vaccine contains a weakened strain of yellow fever virus (17D strain) that replicates in vaccinated individuals but does not cause disease in immunocompetent people. This triggers both humoral (antibody) and cell-mediated immune responses, providing long-term protection against infection with wild-type yellow fever virus. A single dose typically confers lifelong immunity in most recipients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: